Table 1 Point estimates for incidence of unspecified dose adjustment, dose increase and dose decrease for individual studies included in the systematic review

Allegra 2017 [48]

Control (N = 99)

72.7 (64.0, 81.5)

–

–

Nomogram^b (N = 92)

60.9 (50.9, 70.8)

–

–

Buhler 2014 [49]

(N = 2074)

–

4.8 (3.9, 5.7)

3.7 (2.9, 4.5)

Magnusson 2017 [58]

AMH (N = 152)

54.6 (46.7, 62.5)

–

–

Non-AMH (N = 155)

52.3 (44.4, 60.1)

–

–

Espinós 2017^c [52]

(N = 41)

26.8 (13.3, 40.4)

–

–

Nyboe Andersen 2017 [9]

r-hFSH (N = 661)

36.8 (33.1, 40.4)

–

–

Rettenbacher 2015 [62]

Bemfola (N = 220)

–

–

17.3 (12.3, 22.3)

GONAL-f (N = 113)

–

–

14.2 (7.7, 20.6)

Strowitzki 2016 [63]

Ovaleap (N = 153)

–

35.9 (28.3, 43.6)

15.0 (9.4, 20.7)

GONAL-f (N = 146)

–

43.2 (35.1, 51.2)

15.1 (9.3, 20.9)

Devroey 2012 [50]

r-hFSH (N = 375)

24.8 (20.4, 29.2)

2.1 (0.7, 3.6)

Durnerin 2008 [51]

Control (N = 49)

–

55.1 (41.2, 69.0)

2.0 (−1.9, 6.0)

r-hLH pretreat (N = 53)

–

54.7 (41.3, 68.1)

3.8 (−1.4, 8.9)

Esteves 2009 [53]

r-hFSH (N = 236)

–

–

53.4 (47.0, 59.8)

Devroey 2009 [54]

r-hFSH (N = 750)

–

–

8.4 (6.4, 10.4%)

Freiesleben 2008 [55]

r-hFSH (N = 159)

44.0 (36.3, 51.7)

–

–

Kyrou 2009 [56]

r-hFSH (N = 230)

–

3.0 (0.8, 5.3)

7.0 (3.7, 10.2)

Lossl 2008 [57]

Androgen priming (N = 53)

–

58.5 (45.2, 71.8)

1.9 (−1.8, 5.5)

Control (N = 50)

–

52.0 (38.2, 65.8)

2.0 (−1.9, 5.9)

Nakhuda 2010^d [59]

(N = 104)

–

10.6 (4.7, 16.5)

35.6 (26.4, 44.8)

Nyboe Andersen 2008 [60]

r-hFSH (N = 261)

–

51.7 (45.7, 57.8)

11.5 (7.6, 15.4)

r-hFSH + r-hLH (N = 265)

–

48.7 (42.7, 54.7)

11.3 (7.5, 15.1)

Requena 2010 [61]

r-hFSH + HP-hMG (N = 46)

–

32.6 (19.1, 46.2)

–

r-hFSH (N = 46)

–

32.6 (19.1, 46.2)

–

Yovich 2012 [40]

FSH dose < 100 IU (N = 47)

–

53.2 (38.9, 67.5)

–